References
- Chopra V, Marmur JD, Cavusoglu E. The role of clopidogrel in the management of patients with ischemic heart disease. Cardiovasc Drugs Ther 2003; 17(5–6)467–477
- Lerner RG, Frishman WH, Mohan KT. Clopidogrel: a new antiplatelet drug. Heart Dis 2000; 2(2)168–173
- Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100(15)1667–1672
- Coukell AJ, Markham A. Clopidogrel. Drugs 1997; 54(5)745–750
- Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75(2)328–338
- Ringleb PA, Schellinger PD, Schwark C. Clopidogrel in the management of cerebrovascular events. Int J Clin Pract 2004; 58(4)402–410
- Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2-methylthio ADP to rat platelets – effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994; 269(2)772–777
- Savi P, Heilmann E, Nurden P, Laplace MC, Bihour C, Kieffer G, Nurden AT, Herbert JM. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb Hemost 1996; 2(1)35–42
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038)1329–1339
- Mehta SR, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003; 41(4 Suppl S)79S–88S
- Jonas S, Grieco G. Editorial comment – an approach to the estimation of the risk of TTP during clopidogrel therapy. Stroke 2004; 35(2)537–538